Uncategorized-EN
How to improve quality of life during and after radiotherapy? Sarcoma practice and research in large university clinics in Toronto and Berlin
The winner of this year’s research grant of the German Sarcoma Foundation, Dr. Siyer Roohani, decided to go to Canada to deepen his sarcoma expertise. A soon-to-be radiation oncology specialist for sarcoma in Germany, he currently works and researches as a clinical scholar at one of the largest sarcoma centres in the world, the Princess Margaret Cancer Centre in Toronto, Canada. In a chat with Voices of Sarcoma, he explains why he totally encourages any young scientist to do a work stay abroad, especially those wanting to specialize in sarcoma.
Read MoreFaR-RMS
FaR-RMS: An Overarching Study for Children and Adults with Frontline and Relapsed RhabdoMyoSarcoma Agents: Several drug regimes, including Irinotecan, Actinomycin D, Doxorubicin, Ifosfamide, Vincristine, Vinorelbine, Cyclophosphamide, Temozolomide, radiotherapy, Regorafenib Phase III Status Recruiting Sponsor University of Birmingham For further information please also consult https://www.clinicaltrials.gov/study/NCT06797999 FaR-RMS is an over-arching study for children and adults with newly…
Read MoreUSA: TGCT Support
USA: TGCT Support Back to members Organisation Profile TGCT Support is committed to enhancing treatment options and quality of life for people living with Tenosynovial Giant Cell Tumor (TGCT) through patient-powered research, education and empowerment, and global advocacy efforts. Our vision is to empower a future fueled by data, guiding our journey toward advancement…
Read MoreUSA: GCT Support
USA: GCT Support Back to members Organisation Profile GCT Support is committed to enhancing treatment options and quality of life for people living with Giant Cell Tumor of the Bone (GCT) through patient-powered research, education and empowerment, and global advocacy efforts. Our vision is to empower a future fueled by data, guiding our…
Read MoreROGER EXPLORES… Whole Genome Sequencing: Hopes are high, but limitations (still) a reality
Roger Wilson is an eminent figure in the national and international sarcoma patient advocacy world. Diagnosed in 1999 with a soft tissue sarcoma followed by multiple relapses and operations, Roger is recognized for his knowledge in sarcoma matters. He founded Sarcoma UK, has published many articles, shaped patient-led research and advocacy work, and he is the mastermind behind the concept of Sarcoma Intelligent Specialist Networks (SISN). Roger will share with us from time to time his insights and opinions on sarcoma matters in ROGER EXPLORES… He starts off by examining what’s happening with whole genome sequencing and why it is not the answer to everything, yet! A must read!
Read MoreAn award-winning ‘Manifesto against Sarcomas’: ASARGA campaigns against inequality in sarcoma care in Spain
The winner of this year’s Advocacy in Action Award, ASARGA, is fighting for more equitable access to early diagnosis and better care throughout the country in Spain. The Sarcoma Patient Advocacy Care Group mobilized 3000 supporters for their advocacy initiative to lobby policy makers. Natalia Fernández tells us the story of ASARGA and their efforts to include sarcoma care in Spain’s National Health System Cancer strategy.
Read MoreUSA: Pittsburgh Cure Sarcoma
USA: Pittsburgh Cure Sarcoma Back to members Organisation Profile Our Mission: Raise awareness of childhood and adult sarcoma and fund research in the Pittsburgh region and beyond. In January 2011, Drs. Hussein Tawbi and Kurt Weiss, with the UPMC Hillman Cancer Center, along with a start-up committee of 12 members, joined with the Sarcoma…
Read MoreUSA: Liposarcoma Support Network
USA: Liposarcoma Support Network Back to members Organisation Profile The Liposarcoma Support Network (LSN) – Program by the Life Raft Group The Liposarcoma Support Network (LSN) is committed to enhancing the survival and quality of life for people living with liposarcoma through patient-powered research, education and empowerment, and global advocacy efforts. Our vision is…
Read MoreFOG-001 in Locally Advanced or Metastatic Solid Tumors
Agents: FOG-001 Phase I/II Status Recruiting Sponsor Parabilis Medicines, Inc. For further information please also consult https://clinicaltrials.gov/study/NCT05919264 This phase 1/2 (first in human), open-label, non-randomized, dose escalation and dose expansion study evaluates the safety, tolerability, PK, pharmacodynamics, and antitumor activity of FOG-001 in patients with advanced or metastatic solid tumors likely or known to have…
Read MoreADCElerate1
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma (ADCElerate1) Agents: ADCE-D01 Phase I/II Status Recruiting Sponsor Adcendo ApS For further information please also consult https://www.clinicaltrials.gov/study/NCT06797999 ADCElerate1 is a first-in-human, phase 1/2, open-label, dose escalation and expansion study to evaluate the safety, pharmacokinetics, and antitumor activity of ADCE-D01 in patients with metastatic and/or unresectable soft tissue sarcoma. ADCE-D01…
Read More